| MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma ME Hegi, AC Diserens, T Gorlia, MF Hamou, N De Tribolet, M Weller, ... New England Journal of Medicine 352 (10), 997-1003, 2005 | 8732 | 2005 |
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the … R Stupp, ME Hegi, WP Mason, MJ Van Den Bent, MJB Taphoorn, ... The lancet oncology 10 (5), 459-466, 2009 | 8418 | 2009 |
| Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial R Stupp, S Taillibert, A Kanner, W Read, DM Steinberg, B Lhermitte, ... Jama 318 (23), 2306-2316, 2017 | 2360 | 2017 |
| Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial A Malmström, BH Grønberg, C Marosi, R Stupp, D Frappaz, H Schultz, ... The lancet oncology 13 (9), 916-926, 2012 | 1506* | 2012 |
| EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood M Weller, M van den Bent, M Preusser, E Le Rhun, JC Tonn, G Minniti, ... Nature reviews Clinical oncology 18 (3), 170-186, 2021 | 1426 | 2021 |
| Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial R Stupp, S Taillibert, AA Kanner, S Kesari, DM Steinberg, SA Toms, ... Jama 314 (23), 2535-2543, 2015 | 1351 | 2015 |
| European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of … R Stupp, ME Hegi, WP Mason, MJ Van den Bent, MJ Taphoorn, ... Lancet Oncol 10 (5), 459-466, 2009 | 1147 | 2009 |
| Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial MR Gilbert, M Wang, KD Aldape, R Stupp, ME Hegi, KA Jaeckle, ... Journal of clinical oncology 31 (32), 4085-4091, 2013 | 1125 | 2013 |
| Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre … R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ... The lancet oncology 15 (10), 1100-1108, 2014 | 1074 | 2014 |
| European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas M Weller, M Van Den Bent, JC Tonn, R Stupp, M Preusser, ... The lancet oncology 18 (6), e315-e329, 2017 | 1063 | 2017 |
| Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate … ME Hegi, L Liu, JG Herman, R Stupp, W Wick, M Weller, MP Mehta, ... Journal of clinical oncology 26 (25), 4189-4199, 2008 | 1037 | 2008 |
| Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide ME Hegi, AC Diserens, S Godard, PY Dietrich, L Regli, S Ostermann, ... Clinical cancer research 10 (6), 1871-1874, 2004 | 1025 | 2004 |
| Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions PY Wen, M Weller, EQ Lee, BM Alexander, JS Barnholtz-Sloan, ... Neuro-oncology 22 (8), 1073-1113, 2020 | 906 | 2020 |
| MGMT promoter methylation in malignant gliomas: ready for personalized medicine? M Weller, R Stupp, G Reifenberger, AA Brandes, MJ Van Den Bent, ... Nature Reviews Neurology 6 (1), 39-51, 2010 | 889 | 2010 |
| Stem cell–related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma A Murat, E Migliavacca, T Gorlia, WL Lambiv, T Shay, MF Hamou, ... Journal of clinical oncology 26 (18), 3015-3024, 2008 | 820 | 2008 |
| Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells F Klemm, RR Maas, RL Bowman, M Kornete, K Soukup, S Nassiri, ... Cell 181 (7), 1643-1660. e17, 2020 | 758 | 2020 |
| Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22 LA Cannon-Albright, DE Goldgar, LJ Meyer, CM Lewis, DE Anderson, ... Science 258 (5085), 1148-1152, 1992 | 706 | 1992 |
| Chemoradiotherapy in malignant glioma: standard of care and future directions R Stupp, ME Hegi, MR Gilbert, A Chakravarti Journal of Clinical Oncology 25 (26), 4127-4136, 2007 | 677 | 2007 |
| Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE. 3 T Gorlia, MJ van den Bent, ME Hegi, RO Mirimanoff, M Weller, ... The lancet oncology 9 (1), 29-38, 2008 | 648 | 2008 |
| In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. M Harvey, AT Sands, RS Weiss, ME Hegi, RW Wiseman, P Pantazis, ... Oncogene 8 (9), 2457-2467, 1993 | 627 | 1993 |
